TFPI and gastric cancer: The m6A reader protein YTHDF2 mediates the m6A modification of ONECUT2 mRNA, thereby activating TFPI transcription, leading to stemness in gastric cancer and resistance to oxaliplatin, providing a new treatment target to tackle gastric cancer that is resistant to oxaliplatin (Fan et al., 2025).